Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Rating of “Moderate Buy” from Analysts

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has earned a consensus rating of “Moderate Buy” from the thirteen ratings firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $351.67.

MDGL has been the topic of a number of recent analyst reports. JMP Securities reiterated a “market outperform” rating and issued a $427.00 price objective on shares of Madrigal Pharmaceuticals in a report on Friday, January 10th. UBS Group upped their price target on Madrigal Pharmaceuticals from $411.00 to $441.00 and gave the company a “buy” rating in a research note on Friday, November 1st. B. Riley raised their price objective on Madrigal Pharmaceuticals from $194.00 to $236.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. StockNews.com upgraded shares of Madrigal Pharmaceuticals to a “sell” rating in a report on Saturday, October 12th. Finally, HC Wainwright increased their target price on shares of Madrigal Pharmaceuticals from $390.00 to $400.00 and gave the stock a “buy” rating in a research note on Tuesday, January 14th.

Insider Activity at Madrigal Pharmaceuticals

In related news, Director Fred B. Craves sold 3,400 shares of Madrigal Pharmaceuticals stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $350.30, for a total value of $1,191,020.00. Following the completion of the transaction, the director now owns 14,600 shares in the company, valued at $5,114,380. The trade was a 18.89 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Carole Huntsman sold 347 shares of the business’s stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $335.24, for a total transaction of $116,328.28. Following the transaction, the insider now owns 10,438 shares of the company’s stock, valued at $3,499,235.12. This trade represents a 3.22 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 12,090 shares of company stock worth $3,883,621. Company insiders own 22.80% of the company’s stock.

Institutional Trading of Madrigal Pharmaceuticals

A number of institutional investors have recently bought and sold shares of MDGL. Kornitzer Capital Management Inc. KS purchased a new stake in shares of Madrigal Pharmaceuticals during the 4th quarter worth approximately $4,554,000. D.A. Davidson & CO. acquired a new stake in Madrigal Pharmaceuticals during the 4th quarter worth $221,000. Sanctuary Advisors LLC lifted its position in Madrigal Pharmaceuticals by 5.2% in the fourth quarter. Sanctuary Advisors LLC now owns 1,247 shares of the biopharmaceutical company’s stock valued at $422,000 after acquiring an additional 62 shares during the last quarter. Rhumbline Advisers boosted its stake in Madrigal Pharmaceuticals by 1.0% in the fourth quarter. Rhumbline Advisers now owns 24,440 shares of the biopharmaceutical company’s stock valued at $7,541,000 after acquiring an additional 243 shares in the last quarter. Finally, Newbridge Financial Services Group Inc. purchased a new position in shares of Madrigal Pharmaceuticals during the fourth quarter worth about $1,297,000. 98.50% of the stock is owned by hedge funds and other institutional investors.

Madrigal Pharmaceuticals Stock Down 1.0 %

Shares of MDGL opened at $334.80 on Friday. Madrigal Pharmaceuticals has a 52-week low of $168.25 and a 52-week high of $368.29. The company has a quick ratio of 5.93, a current ratio of 5.98 and a debt-to-equity ratio of 0.15. The stock has a fifty day simple moving average of $314.92 and a two-hundred day simple moving average of $275.57. The company has a market capitalization of $7.30 billion, a PE ratio of -13.35 and a beta of -0.36.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($4.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($6.94) by $2.02. The firm had revenue of $62.18 million for the quarter, compared to analyst estimates of $34.60 million. During the same quarter in the previous year, the business posted ($5.34) earnings per share. As a group, equities analysts forecast that Madrigal Pharmaceuticals will post -23.64 EPS for the current year.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.